Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model

Nature Materials

Volumn 15, Issue 10, 2016, Pages 1128-1138

  Conde, João ^a,b   Oliva, Nuria ^a   Zhang, Yi ^a   Artzi, Natalie ^a,c,d  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; FIBER OPTIC SENSORS; GOLD; HYDROGELS; INFRARED DEVICES; INFRARED RADIATION; METAL NANOPARTICLES; NANOPARTICLES; TUMORS;

ADHESIVE HYDROGELS; ANTI-CANCER AGENTS; DISEASE PROGRESSION; EMBEDDED NANOPARTICLES; GOLD NANOPARTICLES; NEAR-INFRARED RADIATIONS; SYSTEMIC DELIVERIES; TRIPLE COMBINATIONS;

DISEASES;

GOLD; KRAS PROTEIN, HUMAN; METAL NANOPARTICLE; PROTEIN P21; SMALL INTERFERING RNA;

ANIMAL; CHEMISTRY; COLON TUMOR; DEFICIENCY; DISEASE MODEL; GENE THERAPY; GENETICS; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; PHOTOTHERAPY; RECURRENT DISEASE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GOLD; MALE; METAL NANOPARTICLES; MICE; PHOTOTHERAPY; PROTO-ONCOGENE PROTEINS P21(RAS); RECURRENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84979645219     PISSN: 14761122     EISSN: 14764660     Source Type: Journal    
DOI: 10.1038/nmat4707     Document Type: Article

References (41)

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30 (2016).
2. Kistler, C. E. Colorectal-cancer incidence and mortality after screening. N. Engl. J. Med. 369, 2354-2354 (2013).
3. Kountouras, J., Zavos, C. & Chatzopoulos, D. Therapy for colorectal cancer. N. Engl. J. Med. 352, 1820-1821 (2005).
4. Minelli, C., Lowe, S. B. & Stevens, M. M. Engineering nanocomposite materials for cancer therapy. Small 6, 2336-2357 (2010).
5. Liu, Y., Miyoshi, H. & Nakamura, M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 120, 2527-2537 (2007).
6. Conde, J., Oliva, N., Atilano, M., Song, H. S. & Artzi, N. Self-Assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nature Mater. 15, 353-363 (2016).
7. Howes, P. D., Chandrawati, R. & Stevens, M. M. Colloidal nanoparticles as advanced biological sensors. Science 346, 1247390 (2014).
8. Wu, S. Y., Lopez-Berestein, G., Calin, G. A. & Sood, A. K. RNAi therapies: drugging the undruggable. Sci. Transl. Med. 6, 240ps7 (2014).
9. Bertrand, N.,Wu, J., Xu, X., Kamaly, N. & Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25 (2014).
10. Conde, J., Edelman, E. R. & Artzi, N. Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-All-trades in cancer nanotheranostics? Adv. Drug Deliv. Rev. 81, 169-183 (2015).
11. Oliva, N. et al. Regulation of dendrimer/dextran material performance by altered tissue microenvironment in inflammation and neoplasia. Sci. Transl. Med. 7, 272ra211 (2015).
12. Segovia, N. et al. Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer. Adv. Healthc. Mater. 4, 271-280 (2015).
13. Conde, J., Oliva, N. & Artzi, N. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. Proc. Natl Acad. Sci. USA 112, E1278-E1287 (2015).
14. Artzi, N. et al. In vivo and in vitro tracking of erosion in biodegradable materials using non-invasive fluorescence imaging. Nature Mater. 10, 704-709 (2011).
15. Artzi, N., Shazly, T., Baker, A. B., Bon, A. & Edelman, E. R. Aldehyde-Amine chemistry enables modulated biosealants with tissue-specific adhesion. Adv. Mater. 21, 3399-3403 (2009).
16. von Maltzahn, G. et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 69, 3892-3900 (2009).
17. Huang, X., El-Sayed, I. H., Qian,W. & El-Sayed, M. A. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 128, 2115-2120 (2006).
18. von, M. G. et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nature Mater. 10, 545-552 (2011).
19. Sonpavde, G. Bevacizumab in colorectal cancer. N. Engl. J. Med. 351, 1690 (2004).
20. Wang, Y., Fei, D., Vanderlaan, M. & Song, A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7, 335-345 (2004).
21. Li, Z. J. et al. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J. Control. Release 148, 292-302 (2010).
22. Sunakawa, Y., Lenz, H. J. & Ichikawa,W. RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 2159 (2013).
23. Bosch, F. X., Garten,W., Klenk, H. D. & Rott, R. Proteolytic cleavage of influenza-virus hemagglutinins-primary structure of the connecting peptide between Ha1 and Ha2 determines proteolytic cleavability and pathogenicity of avian influenza-viruses. Virology 113, 725-735 (1981).
24. Oliva, N. et al. Natural tissue microenvironmental conditions modulate adhesive material performance. Langmuir 28, 15402-15409 (2012).
25. Wang, Y. H. et al. Synergistic delivery of gold nanorods using multifunctional microbubbles for enhanced plasmonic photothermal therapy. Sci. Rep. 4, 5685 (2014).
26. Kuo,W. S. et al. Gold nanorods in photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. Angew. Chem. Int. Ed. Engl. 49, 2711-2715 (2010).
27. Chong, P. S. & Finlay, I. G. Surgical options in the management of advanced and recurrent colorectal cancer. Surg. Oncol. 16, 25-31 (2007).
28. Chokshi, R. J., Abdel-Misih, S. & Bloomston, M. Surgical management of colorectal cancer: a review of the literature. Indian J. Surg. 71, 350-355 (2009).
29. Mocellin, S. Microarray Technology and Cancer Gene Profiling. Advances in Experimental Medicine and Biology (Springer, 2007).
30. Adiconis, X. et al. Comparative analysis of RNA sequencing methods for degraded or low-input samples. Nature Methods 10, 623-629 (2013).
31. Hemmat, M. et al. Short stature, digit anomalies and dysmorphic facial features are associated with the duplication of miR-17 92 cluster. Mol. Cytogenet. 7, 27 (2014).
32. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
33. Mendell, J. T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 133, 217-222 (2008).
34. Hatakeyama, H. et al. A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response. Mol. Ther. 19, 1487-1498 (2011).
35. Meerzaman, D. M. et al. Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma. Cancer Genomics Proteomics 11, 1-12 (2014).
36. Voloshanenko, O. et al.Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nature Commun. 4, 2610 (2013).
37. Herath, N. I., Doecke, J., Spanevello, M. D., Leggett, B. A. & Boyd, A.W. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br. J. Cancer 100, 1095-1102 (2009).
38. Kok-Sin, T. et al. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncol. Rep. 34, 22-32 (2015).
39. Sturn, A., Quackenbush, J. & Trajanoski, Z. Genesis: cluster analysis of microarray data. Bioinformatics 18, 207-208 (2002).
40. Mootha, V. K. et al. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet. 34, 267-273 (2003).
41. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).